ArticlePloS one2013
Zoledronic acid enhances lipopolysaccharide-stimulated proinflammatory reactions through controlled expression of SOCS1 in macrophages.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Zoledronate enhances lipopolysaccharide-induced inflammation via toll-like receptor 4 upregulation.Journal of dental sciences · 2026Article
- Fluvastatin enhances healing of medication-related osteonecrosis of the jaw (MRONJ) via macrophage polarization in a rat MRONJ-like model.Journal of dental sciences · 2026Article
- Influence of antiresorptive/antiangiogenic therapy on changes in periodontal and oral tissue structures: a histomorphometrical analysis in rats.Clinical oral investigations · 2023Article
- Influence of antiresorptive/antiangiogenic therapy on the surgical treatment outcomes of experimentally induced peri-implantitis lesions.Clinical oral investigations · 2023Article
- Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid.International journal of molecular sciences · 2023Article
- Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.International journal of molecular sciences · 2023Review
- Medication-Related Osteonecrosis: Why the Jawbone?Dentistry journal · 2023Review
- Reduced Expression of Natural Killer Cell-Related Activating Receptors by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer and Their Improvement by Zoledronic Acid.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Macrophage Involvement in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Comprehensive, Short Review.Cancers · 2022Review
- IFN-β mediates the anti-osteoclastic effect of bisphosphonates and dexamethasone.Frontiers in pharmacology · 2022Article
- IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.NPJ breast cancer · 2021Article
- Changes in peripheral monocyte populations 48-72 hours after subcutaneous denosumab administration in women with osteoporosis.Journal of musculoskeletal & neuronal interactions · 2020Article
- Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Suppressors of cytokine signalling (SOCS)-1 inhibits neuroinflammation by regulating ROS and TLR4 in BV2 cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- Zoledronic acid regulates the synthesis and secretion of IL-1β through Histone methylation in macrophages.Cell death discovery · 2020Article
- Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts.International journal of medical sciences · 2019Article
- Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice.The American journal of pathology · 2018Article
- Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.The Journal of international medical research · 2018Review
- Anti-inflammatory effect of polydeoxyribonucleotide on zoledronic acid-pretreated and lipopolysaccharide-stimulated RAW 264.7 cells.Experimental and therapeutic medicine · 2018Article
- Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.Archives of toxicology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect of nitrogen-containing bisphosphonate (NBP) use. Many studies have shown that BRONJ is limited to the jawbone and does not occur in the other bones. We hypothesized that BRONJ is related to local bacterial iections and involves the innate immune system. To examine the relationship between BRONJ and innate immunity, we examined the effects of NBPs on macrophages, one of the important cell types in innate immunity. The expression of toll-like receptor-4 (TLR4) in cells after pretreatment with zoledronic acid (ZOL) did not considerably differ from that in untreated control cells. However, cytokine levels and nitric oxide (NO) production increased after pretreatment with ZOL. Furthermore, ZOL induced NF-κB activation by enhancing IκB-α degradation. Lipopolysaccharide (LPS)-induced apoptosis also increased after pretreatment with ZOL. This effect was mediated by a reduction of suppressor of cytokine signaling-1 (SOCS1), which is a negative regulator of myeloid differentiation primary response gene 88 (MyD 88)-dependent signaling. These results suggest that ZOL induced excessive innate immune response and proinflammatory cytokine production and that these processes may be involved in the bone destruction observed in BRONJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.